You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

 

414 Results
Drug
Other Name(s): Erleada®
Jan 2025
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Palliative
Funding:
Exceptional Access Program
    apalutamide - For the treatment of non-metastatic castration resistant prostate cancer (nmCRPC), based on criteria
Exceptional Access Program
    apalutamide - For the treatment of metastatic castration sensitive prostate cancer (mCSPC), based on criteria
Jan 2025
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal
Intent: Neoadjuvant
Nov 2023
Regimen
Cancer Type:
Gastrointestinal, 
Hepatobiliary / Liver / Bile Duct
Intent: Palliative
Document
Document
If you got a letter from ColonCancerCheck with an abnormal fecal immunochemical test (FIT) result, the information on this page can help you...
Guidelines and Advice
Dec 1969

Pages